RT @charlie_lees: Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minu…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minu…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minu…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minu…
RT @charlie_lees: Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minu…
Have you seen the new data from @clarityibd released today as a pre-print? Check out the YouTube link below for 20 minutes on what these data mean, plus links to the 2 full papers. A short film geared for patients is coming later this evening.
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
@getgutsycanada Hi, please consider discussing the following studies with your experts. A "meh" news and a good one. The "meh": https://t.co/vQu0hOy7hn
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
RT @charlie_lees: Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological resp…
@GYamey An example: https://t.co/vQu0hOy7hn
Resumen sobre la respuesta serológica al SARS-CoV2 y a las vacunas. Gracias 😍
Anti-TNF & COVID-19 @clarityibd IFX vs VEDO in IBD (n=7226) Two important publications in a week. 1) serological response to SARS-CoV2 infection https://t.co/vQ3Tkwm52w 2) immune response to vaccination https://t.co/MFhkgZMNv8 All explained here:
RT @SDHResearch: Results from the @clarityibd study out - well done to the team @SalisburyNHS for your contributions, and thanks, as always…
@StephaneKM Ça semble assez clair désormais... "oUé MaIs lEs BiO c’EsT tOp, Ça pRéViEnT lA cYtOkInE sToRM." https://t.co/vQu0hOy7hn
RT @bmj_company: Infliximab, a powerful biologic that is used to treat inflammatory bowel disease (IBD), blunts the body’s immune response…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @h_sokol: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab! https://t.co/W8RMBbJ3PE
RT @epidatum: Anti-#SARSCoV2 antibody responses are attenuated in patients with IBD treated with #infliximab Infliximab is associated wit…
RT @bioactive: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab | Gut https://t.co/WhUQ4jqpL5
RT @Werrzz: @Karl_Lauterbach https://t.co/Q28kDa2b1o "Extending the interval between COVID-19 vaccine doses may pose a risk to the elderly…
@Karl_Lauterbach https://t.co/Q28kDa2b1o "Extending the interval between COVID-19 vaccine doses may pose a risk to the elderly due to lower vaccine immunogenicity in this group. We recommend that second doses not be delayed in elderly individuals."
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @DelthiaRicks: Biologic drug prescribed for inflammatory bowel disease blunts the immune response to Covid infection. Infliximab is a p…
RT @MaiaKayalMD: Thursday AM @MSHS_IBDCenter #YoungInvestigator meeting led by the most youthful investigator @JeanFredericCo1. Discussing…
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab | Gut https://t.co/WhUQ4jqpL5
RT @DelthiaRicks: Biologic drug prescribed for inflammatory bowel disease blunts the immune response to Covid infection. Infliximab is a p…
Anti-#SARSCoV2 antibody responses are attenuated in patients with IBD treated with #infliximab Infliximab is associated with attenuated serological responses to #COVID19 that were further blunted by immunomodulators used as concomitant therapy. https://
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @MaiaKayalMD: Thursday AM @MSHS_IBDCenter #YoungInvestigator meeting led by the most youthful investigator @JeanFredericCo1. Discussing…
Thursday AM @MSHS_IBDCenter #YoungInvestigator meeting led by the most youthful investigator @JeanFredericCo1. Discussing #ClarityIBD recent work. https://t.co/0cwuTdyAc9
RT @h_sokol: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab! https://t.co/W8RMBbJ3PE
RT @h_sokol: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab! https://t.co/W8RMBbJ3PE
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab! https://t.co/W8RMBbJ3PE
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
A very informative and well-written article. Thank you, Dr. Weizman, for sharing this.
RT @IBD_FloMD: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab https://t.co/s8IVo7ugSh
RT @IBD_FloMD: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab https://t.co/s8IVo7ugSh
Do we think the lower antibody response is clinically relevant ?
RT @Swaminath_IBD: Hot off the press: Similar rates of #COVID infection in Vedo and IFX #IBD patients, however lower antibody responses in…
RT @kaan_levin: #infliksimab ilacının COVID-19 olan hastalar ve aşı olanlarda vücudun Antikor üretimini çok zayıflattığı yapılan çalişmalar…
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
RT @DrAnkurSriv: Delighted that @ResearchNBT @NorthBristolNHS contributed to this important COVID-19 study for patients with IBD. #NBTproud…
#infliksimab ilacının COVID-19 olan hastalar ve aşı olanlarda vücudun Antikor üretimini çok zayıflattığı yapılan çalişmalarda ortaya çıktı. Bu durumlarda #vedolizumab ilaci önerilmekte. EMA. Araştırma ve çalişmanın Kaynağı:https://t.co/8uVHaOGXRs
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
Results from the @clarityibd study out - well done to the team @SalisburyNHS for your contributions, and thanks, as always, to those who volunteered to take part
Hot off the press: Similar rates of #COVID infection in Vedo and IFX #IBD patients, however lower antibody responses in IFX patients after infection https://t.co/PwHi9DeGxW
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
RT @GSTTresearch: New research has just been published in @Gut_BMJ on whether a drug for #IBD affects patients' antibody responses to #COVI…
RT @IBDcanruti: Should we vaccinate #immunosuppressed #IBD patients with those vaccines with the highest response rates? @geteccu @fgomoll…
RT @DrPhil_Gu: #COVID19 ab response in IFX vs VDZ treated #IBD pts 📍Similar rates of 🤢 📍⬇️seroprevalence in IFX 📍Seroconversion: IFX 48…
RT @DrPhil_Gu: #COVID19 ab response in IFX vs VDZ treated #IBD pts 📍Similar rates of 🤢 📍⬇️seroprevalence in IFX 📍Seroconversion: IFX 48…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @FergaGleeson: @Gut_BMJ @MayoClinicGIHep FYI re 📝 & hot topic re #COVIDー19 🦠😷 & IBD @davebruining @SunandaKaneMD @EdwardLoftus2 @Faubion…
RT @RichardPollok: Amazing effort from research team and IBD nurses @StGeorgesTrust that contributed to this study @clarityibd @Gut_BMJ
RT @bmj_company: Infliximab, a powerful biologic that is used to treat inflammatory bowel disease (IBD), blunts the body’s immune response…
RT @RichardPollok: Amazing effort from research team and IBD nurses @StGeorgesTrust that contributed to this study @clarityibd @Gut_BMJ
RT @RichardPollok: Inspiring effort from team Exeter-spearheaded participation from 7000 patients at 92 UK centres all recruited in 3 month…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @IBDcanruti: Should we vaccinate #immunosuppressed #IBD patients with those vaccines with the highest response rates? @geteccu @fgomoll…
RT @ImperialMDR: An important new paper co-authored by MDR's @NickPowellLab "Anti-SARS-CoV-2 antibody responses are attenuated in patients…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @DelthiaRicks: Biologic drug prescribed for inflammatory bowel disease blunts the immune response to Covid infection. Infliximab is a p…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
Should we vaccinate #immunosuppressed #IBD patients with those vaccines with the highest response rates? @geteccu @fgomollon @Iagorlago @ign76 @VicentHernande9 @anaguticasbas @manu_barreiro @JordiGuardiolac @frmoranta @IBDBellvitge @ManosaMiriam @EIILaPri
Well done to the all involved 👏 especially Liane from our team 😊😊 #teamwork
RT @RichardPollok: Amazing effort from research team and IBD nurses @StGeorgesTrust that contributed to this study @clarityibd @Gut_BMJ htt…
RT @DarrellPardi: Anti-SARS-CoV-2 antibody response attenuated by IBD treatments. Implications for vaccine? https://t.co/XpLVw9PkIr
RT @DelthiaRicks: Biologic drug prescribed for inflammatory bowel disease blunts the immune response to Covid infection. Infliximab is a p…
RT @ExeterMed: 2/3 Read the full paper here: https://t.co/cjImkG7CFP
@Gut_BMJ @MayoClinicGIHep FYI re 📝 & hot topic re #COVIDー19 🦠😷 & IBD @davebruining @SunandaKaneMD @EdwardLoftus2 @FaubionWilliam
RT @ExeterMed: 2/3 Read the full paper here: https://t.co/cjImkG7CFP
RT @john_damianosMD: #IBD pts treated w infliximab have 📍=rates of symptomatic #COVID cf those on VDZ 📍⬇️seroprevalence/conversion +antiSA…
RT @DelthiaRicks: Biologic drug prescribed for inflammatory bowel disease blunts the immune response to Covid infection. Infliximab is a p…
RT @DarrellPardi: Anti-SARS-CoV-2 antibody response attenuated by IBD treatments. Implications for vaccine? https://t.co/XpLVw9PkIr
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @RichardPollok: Inspiring effort from team Exeter-spearheaded participation from 7000 patients at 92 UK centres all recruited in 3 month…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @RichardPollok: Inspiring effort from team Exeter-spearheaded participation from 7000 patients at 92 UK centres all recruited in 3 month…